This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nobel Laureate Roger Kornberg To Chair New ChromaDex Scientific Advisory Board

IRVINE, Calif., July 8, 2014 /PRNewswire/ --  ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has appointed Nobel Laureate Roger Kornberg to Chair the Company's newly formed Scientific Advisory Board ("SAB").

The SAB will be comprised of leading researchers, chemists, biochemists and nutritionists, with an emphasis on those having expertise in nicotinamide riboside ("NR"). The SAB's mission is to assist the Company's management team in maximizing the value of the Company's portfolio of patented ingredients by advising on such matters as scientific and research focus, clinical studies, safety and regulatory, commercialization opportunities, and assessing new potential ingredient technologies.

The ChromaDex SAB will be chaired by Kornberg, a Professor at Stanford Medical School, who was awarded the Nobel Prize in Chemistry in 2006 for his research on the molecular basis of eukaryotic transcription. Dr. Kornberg earned his bachelor's degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an Assistant Professor of Biological Chemistry at Harvard Medical School in 1976, before moving to his present position as Professor of Structural Biology at Stanford Medical School in 1978. 

Kornberg's father, the late Arthur Kornberg, was a professor of biochemistry at Stanford and was awarded the Nobel Prize for physiology or medicine in 1959. He was among the first to investigate nicotinamide riboside more than 60 years while at the NIH.

Kornberg commented, "Given my father's noteworthy early research of nicotinamide riboside, I have been following ChromaDex's progress on developing its NIAGEN™ nicotinamide riboside as well as the enormous amount of published research that speaks to the health benefits of NR. I look forward to working with the other members of the SAB as well as the Company's management."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,628.33 +187.74 1.08%
S&P 500 2,094.93 +27.29 1.32%
NASDAQ 5,095.59 +55.8140 1.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs